This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Varian Medical Systems Highlights A Comprehensive Product Portfolio For The Non-Invasive Treatment Of Lung Cancer

BOSTON, Oct. 31, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) highlighted the company's technologies for the non-invasive treatment of lung cancer at the 54 th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week.  Many of Varian's cancer treatment systems can be utilized for attacking lung tumors—which often move during treatment—very precisely, with carefully-shaped, high dose X-ray beams.

"Our latest treatment systems have integrated tools designed for 3- and 4-D imaging, treatment planning, patient positioning, treatment delivery, and motion management, including high resolution beam-shaping and real-time tumor tracking," says Kolleen Kennedy, president of Varian's Oncology Systems business. "These capabilities will further enable efficient, accurate treatments for some forms of lung cancer.  Clinicians will be able to use them to more efficiently plan and deliver a personalized radiotherapy or radiosurgery treatment based on each patient's clinical needs."

Lung Cancer Treatment Technologies

Numerous Varian technologies that were on display at ASTRO this year are particularly applicable for planning and delivering lung cancer treatments.  They include solutions for patient positioning, motion management, and treatment planning, as follows:

Patient Positioning
  • The PerfectPitch™ six-degrees-of-freedom (6DoF) treatment couch, * which was designed to provide access to tumors from more angles, giving clinicians more flexibility for carrying out stereotactic radiosurgery procedures for lung and other tumors.  It will be fully integrated into the newly-launched EDGE™ Radiosurgery Suite * and is also available for the TrueBeam™ system.

Motion Management
  • An advanced motion management package, * available on the EDGE and TrueBeam systems, which offers clinicians more options for using real-time imaging during radiotherapy treatments.  It also enables expanded use of fluoroscopy and 4-D cone-beam CT—imaging techniques that show motion over time—to better compensate for tumor motion during treatment.
  • The newly enhanced Calypso® system * for real-time tracking of tumors that are subject to respiratory motion, which enables adaptation if the magnitude of tumor motion changes during a treatment, and is compatible with the couch rotations that are often used to optimize targeting during stereotactic treatments in the lung.
  • Calypso anchored Beacon® transponders *, which are position signaling devices that can be implanted in the lung, as well as surface Beacon transponders, allowing different approaches to real-time tracking of respiratory and other patient motion during treatment.

Treatment Planning
  • Treatment planning tools now include thoracic anatomy templates and automated contouring of 4-D CT images (which obviates the need to draw contours manually on multiple image sets from each phase of the respiratory cycle).
  • Acuros™ dose calculation algorithm for accurate dose calculations in areas like the lung, where tissue density varies, as well as analytical tools that enable clinicians to determine the dose levels likely to reach nearby critical organs when treating tumors that shift position from day to day.

Lung Cancer Treatment Research and Education

"Clinical evidence has been accruing to support the use of stereotactic body radiation therapy (SBRT) in the treatment of lung cancer—especially inoperable early-stage non-small cell lung cancer," Kennedy points out. [1] ,[2]  "As a leading provider of technology for these types of non-invasive treatments, Varian has launched a broad lung cancer initiative that encompasses research and education, as well as technology development."

Varian is currently supporting an NCI-sponsored trial comparing surgery with SBRT for the treatment of high-risk operable early-stage cases.  The company is also planning a series of physician education webinars and regional symposia to offer insight into the rationale for lung SBRT, along with information about a new code that reimburses physicians for collaborating with radiation oncologists in the lung cancer treatment planning process. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs